Blood Aluminum Levels in Patients with Hemodialysis and Peritoneal Dialysis

Po-Hsun Chuang, Kai-Fan Tsai, I-Kuan Wang, Ya-Ching Huang, Lan-Mei Huang, Shou-Hsuan Liu, Cheng-Hao Weng, Wen-Hung Huang, Ching-Wei Hsu, Wen-Chin Lee and Tzung-Hai Yen
Additional contact information
Po-Hsun Chuang: Department of Nephrology, Clinical Poison Center, Chang Gung Memorial Hospital, Linkou 333, Taiwan
Kai-Fan Tsai: College of Medicine, Chang Gung University, Taoyuan 333, Taiwan
I-Kuan Wang: Department of Nephrology, China Medical University Hospital, Taichung 404, Taiwan
Ya-Ching Huang: College of Medicine, Chang Gung University, Taoyuan 333, Taiwan
Lan-Mei Huang: Department of Nephrology, Clinical Poison Center, Chang Gung Memorial Hospital, Linkou 333, Taiwan
Shou-Hsuan Liu: Department of Nephrology, Clinical Poison Center, Chang Gung Memorial Hospital, Linkou 333, Taiwan
Cheng-Hao Weng: Department of Nephrology, Clinical Poison Center, Chang Gung Memorial Hospital, Linkou 333, Taiwan
Wen-Hung Huang: Department of Nephrology, Clinical Poison Center, Chang Gung Memorial Hospital, Linkou 333, Taiwan
Ching-Wei Hsu: Department of Nephrology, Clinical Poison Center, Chang Gung Memorial Hospital, Linkou 333, Taiwan
Wen-Chin Lee: College of Medicine, Chang Gung University, Taoyuan 333, Taiwan
Tzung-Hai Yen: Department of Nephrology, Clinical Poison Center, Chang Gung Memorial Hospital, Linkou 333, Taiwan

IJERPH, 2022, vol. 19, issue 7, 1-12

Abstract: Background. This retrospective observational study attempted to examine the prevalence of abnormal blood aluminum levels in dialysis patients, and to explore the association of pathogenic factors, such as demographic, clinical, laboratory as well as the use of phosphate binding drugs, drugs for secondary hyperparathyroidism and erythropoiesis-stimulating drugs with the blood aluminum levels. Methods. The study included 1175 patients (874 hemodialysis and 301 peritoneal dialysis), recruited from Chang Gung Memorial Hospital in November 2020. Patients were stratified into two groups by their blood aluminum levels, as normal (<2 µg/dL, n = 1150) or abnormal (≥2 µg/dL, n = 25). Results. The patients aged 60.4 ± 13.2 years and were dialyzed for 8.6 ± 8.1 years. The average blood aluminum level was 1.0 ± 0.4 µg/dL. Patients with abnormal blood aluminum levels received more sevelamer than patients with normal blood aluminum level ( p = 0.014). Patients with abnormal blood aluminum levels had higher platelet count ( p = 0.001), triglyceride ( p < 0.001) and total iron binding capacity ( p = 0.003) than patients with normal blood aluminum levels. Moreover, the cardiothoracic ratio was higher in patients with abnormal blood aluminum levels than patients with normal blood aluminum levels ( p = 0.003). Conclusions. The prevalence of abnormal blood aluminum levels was low at 2.2%. Nevertheless, the linking of cardiothoracic ratio of more than 0.5 as well as elevated blood platelet count and triglyceride level with blood aluminum levels are interesting, and warranted more researches in this area.

Keywords: blood aluminum levels; hemodialysis; peritoneal dialysis; aluminum toxicity (search for similar items in EconPapers)
JEL-codes: I I1 I3 Q Q5 (search for similar items in EconPapers)
Date: 2022
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.mdpi.com/1660-4601/19/7/3885/pdf (application/pdf)
https://www.mdpi.com/1660-4601/19/7/3885/ (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:gam:jijerp:v:19:y:2022:i:7:p:3885-:d:778865

Access Statistics for this article

IJERPH is currently edited by Ms. Jenna Liu

More articles in IJERPH from MDPI
Bibliographic data for series maintained by MDPI Indexing Manager ().